Abstract
Rho GTPase controls multiple signal-transduction pathways involving the actin cytoskeleton and the microtubule cytoskeleton in processes such as the cell cycle, morphogenesis, and cell migration. The activity of Rho GTPases, such as Rac1, Cdc42, and RhoA, is regulated by GTPase-activating proteins (GAPs), guanine nucleotide exchange factors (GEFs), and guanine nucleotide dissociation inhibitor (GDI). The GEFs activate Rho GTPases through exchange of GDP for GTP. A group of the GEF family, CDM-GEF, containing the Dock180 Homology Region 2 (DHR2) domain is subdivided into four groups based on amino acid sequences. One of these subgroups, DOCK-A, includes DOCK1, DOCK2, and DOCK5, and activates Rac1 Rho GTPase. Mouse Dock5 (mDock5) is structurally similar to DOCK1 and composed of 1868 amino acids containing Src homology 3 (SH3), DHR1, DHR2, and a proline-rich (PR) motif. We generated an mDock5-specific antibody, which detected denatured and nascent forms of mDock5. We determined tissue-specific expression patterns and subcellular localization of mDock5 using this antibody. This antibody provides a way to delineate the biological functions of mDock5 in vivo.
Keywords: DOCK family, GEF, mDock5 (PPK) polyclonal antibody
Protein & Peptide Letters
Title: Characterization of an mDock5-Specific Antibody and Tissue-Specific Expression and Subcellular Localization of mDock5
Volume: 17 Issue: 4
Author(s): Eunmin Kim, Jong-Bok Yoon and SungJoo Kim Yoon
Affiliation:
Keywords: DOCK family, GEF, mDock5 (PPK) polyclonal antibody
Abstract: Rho GTPase controls multiple signal-transduction pathways involving the actin cytoskeleton and the microtubule cytoskeleton in processes such as the cell cycle, morphogenesis, and cell migration. The activity of Rho GTPases, such as Rac1, Cdc42, and RhoA, is regulated by GTPase-activating proteins (GAPs), guanine nucleotide exchange factors (GEFs), and guanine nucleotide dissociation inhibitor (GDI). The GEFs activate Rho GTPases through exchange of GDP for GTP. A group of the GEF family, CDM-GEF, containing the Dock180 Homology Region 2 (DHR2) domain is subdivided into four groups based on amino acid sequences. One of these subgroups, DOCK-A, includes DOCK1, DOCK2, and DOCK5, and activates Rac1 Rho GTPase. Mouse Dock5 (mDock5) is structurally similar to DOCK1 and composed of 1868 amino acids containing Src homology 3 (SH3), DHR1, DHR2, and a proline-rich (PR) motif. We generated an mDock5-specific antibody, which detected denatured and nascent forms of mDock5. We determined tissue-specific expression patterns and subcellular localization of mDock5 using this antibody. This antibody provides a way to delineate the biological functions of mDock5 in vivo.
Export Options
About this article
Cite this article as:
Kim Eunmin, Yoon Jong-Bok and Yoon Kim SungJoo, Characterization of an mDock5-Specific Antibody and Tissue-Specific Expression and Subcellular Localization of mDock5, Protein & Peptide Letters 2010; 17 (4) . https://dx.doi.org/10.2174/092986610790963681
DOI https://dx.doi.org/10.2174/092986610790963681 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxicity and Surface Modification of Dendrimers: A Critical Review
Current Drug Delivery Medicinal Plants Towards Modeling Skin Cancer
Current Drug Targets Stem Cell Transplantation in Multiple Myeloma
Current Cancer Drug Targets The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Nanomaterials for Targeted Delivery of Anticancer Drugs: An Overview
Current Nanomaterials Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry FLT3 as a Therapeutic Target in Childhood Acute Leukemia
Current Drug Targets Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA Concurrent Administration of Rituximab and CHOP Chemotherapeutic Agents for Outpatients with CD20-positive Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design FDG-PET/CT Radiomics Models for The Early Prediction of Locoregional Recurrence in Head and Neck Cancer
Current Medical Imaging Diterpenoids from Liverworts and their Biological Activities
Current Organic Chemistry